ecdysone has been researched along with paclitaxel in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Ao, Y; Naumovski, L; Rohde, LH | 1 |
| Fan, Z; Schmidt, M | 1 |
3 other study(ies) available for ecdysone and paclitaxel
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carrier Proteins; Cell Line; Cell Survival; Doxorubicin; Ecdysone; Humans; Kidney; Paclitaxel; Transfection | 2001 |
Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Topics: Cell Cycle Proteins; Cell Division; Cisplatin; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; DNA Mutational Analysis; DNA, Complementary; Dose-Response Relationship, Drug; Ecdysone; Enzyme Inhibitors; Flow Cytometry; Humans; Immunoblotting; Mutation; Paclitaxel; Phosphorylation; Promoter Regions, Genetic; Retinoblastoma Protein; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2001 |